vTv Therapeutics Inc - Ordinary Shares - Class A

NASDAQ:VTVT  
2.34
+0.07 (+3.08%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)139.93M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1 Million
Adjusted EPS-$0.07
See more estimates
10-Day MA$2.40
50-Day MA$2.64
200-Day MA$2.23
See more pivots

vTv Therapeutics Inc - Ordinary Shares - Class A Stock, NASDAQ:VTVT

3980 Premier Drive, Suite 310, High Point, North Carolina 27265
United States of America
Phone: +1.336.841.0300
Number of Employees: 25

Description

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.